Pharmacokinetics and Safety of a Novel Oral Liquid Formulation of 13- cis Retinoic Acid in Children with Neuroblastoma: A Randomized Crossover Clinical Trial
Gareth J Veal, Deborah A Tweddle, Johannes Visser, Julie Errington, Helen Buck, Josephine Marange, Jon Moss, Shiju Joseph, Hussain Mulla, Gareth J Veal, Deborah A Tweddle, Johannes Visser, Julie Errington, Helen Buck, Josephine Marange, Jon Moss, Shiju Joseph, Hussain Mulla
Abstract
(1) Background: 13-cis-retinoic acid (13-CRA) is a key component of neuroblastoma treatment protocols. This randomized crossover study compares the pharmacokinetics (PK), safety and palatability of a novel oral liquid formulation to the current method of extracting 13-CRA from capsules. (2) Methods: Pharmacokinetics was evaluated in two consecutive treatment cycles. Patients were randomized to receive either liquid or capsule formulation on cycle 1 and then crossed over to the alternative formulation on cycle 2. The daily dose was 200 mg/m2, reduced to 160 mg/m2 in patients with weight ≤ 12 kg. (3) Results: A total of 20 children, median (range) age 4.3 (1-11.6) y were recruited. Pharmacokinetic data were pooled and a population model describing the disposition of 13-CRA and 4-oxo-13-CRA was developed. Bioavailability of the liquid formulation was estimated to be 65% higher (95% CI; 51-79%) than the extracted capsule. CmaxSS and AUC(0-12)SS estimates were also significantly higher; mean (95% CI) differences were 489 (144-835) ng/mL and 3933 (2020-5846) ng/mL·h, respectively (p < 0.01). There were no significant differences in reported adverse effects. Parents found dosing considerably easier with liquid formulation. (4) Conclusions: The pharmacokinetics, safety and palatability of a new liquid formulation of 13-CRA compares favorably to 13-CRA extracted from capsules. Clinical Trial Registration: clinicaltrial.gov NCT03291080.
Keywords: 13-CRA; liquid; neuroblastoma; pharmacokinetics.
Conflict of interest statement
Hussain Mulla and Josephine Marange are employees of Nova Laboratories Limited. The other authors declare no competing interests.
Figures
References
- Matthay K.K., Maris J.M., Schleiermacher G., Nakagawara A., Mackall C.L., Diller L., Weiss W.A. Neuroblastoma. Nat. Rev. Dis. Primers. 2016;2:16078. doi: 10.1038/nrdp.2016.78.
- Reynolds C.P., Villablanca J.G., Mauer B.J., Matthay K.K. Retinoid therapy of high-risk neuroblastoma. Cancer Lett. 2003;197:185–192. doi: 10.1016/S0304-3835(03)00108-3.
- Finklestein J.Z., Krailo M.D., Lenarsky C., Ladisch S., Blair G.K., Reynolds C.P., Sitarz A.L., Hammond G.D. 13-cis-Retinoic acid (NSC 122758) in the treatment of children with metastatic neuroblastoma unresponsive to conventional chemotherapy: Report from the Childrens Cancer Study Group. Med. Pediatric Oncol. 1992;20:307–311. doi: 10.1002/mpo.2950200407.
- Matthay K.K., Reynolds C.P., Seeger R.C., Shimada H., Adkins E.S., Haas-Kogan D., Gerbing R.B., London W.B., Villablanca J.G. Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: A Children’s Oncology Group study. J. Clin. Oncol. 2009;27:1007–1013. doi: 10.1200/JCO.2007.13.8925.
- Veal G.J., Cole M., Errington J., Boddy A.V., Pearson A.D.J., Foot A.B.M., Whyman G. Pharmacokinetics and metabolism of 13-cis-retinoic acid (isotretinoin) in children with high-risk neuroblastoma—A study of the United Kingdom Children’s Cancer Study Group. Br. J. Cancer. 2007;96:424–431. doi: 10.1038/sj.bjc.6603554.
- Veal G.J., Errington J., Rowbotham S.E., Illingworth N.A., Malik G., Cole M., Daly A.K., Pearson A.D., Boddy A.V. Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma. Clin. Cancer Res. 2013;19:469–479. doi: 10.1158/1078-0432.CCR-12-2225.
- Mulla H., Buck H., Price L., Parry A., Bell G., Skinner R. ‘Acceptability’ of a new oral suspension formulation of mercaptopurine in children with acute lymphoblastic leukaemia. J. Oncol. Pharm. Pract. 2016;22:387–395. doi: 10.1177/1078155215577808.
- Beal S., Sheiner L.B., Boeckmann A., Bauer R.J. NONMEM User’s Guides. (1989–2009) Icon Development Solutions; Ellicott City, MD, USA: 2009.
- R (Version 3.3.1) Development Core Team . R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; Vienna, Austria: 2016. [(accessed on 20 March 2021)]. Available online: .
- Bergstrand M., Hooker A.C., Wallin J.E., Karlsson M.O. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143–151. doi: 10.1208/s12248-011-9255-z.
- Wang W., Hallow K.M., James D.A. A Tutorial on RxODE: Simulating Differential Equation Pharmacometric Models in R. CPT Pharmacomet. Syst. Pharmacol. 2016;5:3–10. doi: 10.1002/psp4.12052.
- Goodman G.E., Einspahr J.G., Alberts D.S., Davis T.P., Leigh S.A., Chen H.S., Meyskens F.L. Pharmacokinetics of 13-cis-retinoic acid in patients with advanced cancer. Cancer Res. 1982;42:2087–2091.
- van Riet-Nales D.A., Schobben A.F., Vromans H., Egberts T.C., Rademaker C.M. Safe and effective pharmacotherapy in infants and preschool children: Importance of formulation aspects. Arch. Dis. Child. 2016;101:662–669. doi: 10.1136/archdischild-2015-308227.
- Gota V., Chinnaswamy G., Vora T., Rath S., Yadav A., Gurjar M., Veal G., Kurkure P. Pharmacokinetics and pharmacogenetics of 13-cis retinoic acid in Indian high-risk neuroblastoma patients. Cancer Chemother. Pharmacol. 2016;78:763–768. doi: 10.1007/s00280-016-3126-3.
- Cho H., Naranjo A., Van Ryn C., Yang S., Sonawane P., Villablanca J.G., You A.L., Park J.R., Kreissman S., Patrick Reynolds C., et al. Low plasma levels of 13-cis-retinoic acid (isotretinoin) and its active metabolite 4-oxo-13-cis-retinoic acid are associated with lower overall survival of high-risk neuroblastoma patients; Proceedings of the AACR Annual Meeting; Washington, DC, USA. 1–5 April 2017; Abstract nr LB-049.
- Khan A.A., Villablanca J.G., Reynolds C.P., Avramis V.I. Pharmacokinetic studies of 13-cis-retinoic acid in pediatric patients with neuroblastoma following bone marrow transplantation. Cancer Chemother. Pharmacol. 1996;39:34–41. doi: 10.1007/s002800050535.
- Zandvliet A., Schellens J.H.M., Beijnen J.H., Huitema A.D.R. Population pharmacokinetics and pharmacodynamics for treatment optimisation in clinical oncology. Clin. Pharmacokinet. 2008;47:487–513. doi: 10.2165/00003088-200847080-00001.
- Bleyzac N. The use of pharmacokinetic models in paediatric onco-haematology: Effects on clinical outcome through the examples of busulfan and cyclosporine. Fundam. Clin. Pharmacol. 2008;22:605–608. doi: 10.1111/j.1472-8206.2008.00652.x.
- Veal G., Errington J., Tilby M.J., Pearson A.D.J., Foot A.B.M., McDowell H., Ellershaw C., Pizer B., Nowell G.M., Pearson D.G., et al. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carbo-platin for the treatment of solid tumours. Br. J. Cancer. 2007;96:725–731. doi: 10.1038/sj.bjc.6603607.
- Johansson A., Hill N., Perisoglou M., Whelan J., Karlsson M.O., Standing J.F. A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma. Ther. Drug Monit. 2011;33:711–718. doi: 10.1097/FTD.0b013e31823615e1.
Source: PubMed